This article is more than 5 years old. Information may no longer be current.

VIDEO: Astellas executive highlights key ASCO studies, company pipeline

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CHICAGO — Andrew Krivoshik, MD, PhD, senior vice president and oncology therapeutic area head at Astellas Pharma, spoke with HemOnc Today at ASCO Annual Meeting about key data presented this year.

He discussed the EV-201 study, which showed the investigational therapy enfortumab vedotin induced objective response among 44% of patients with locally advanced or metastatic urothelial cancer whose disease progressed after two prior lines of therapy.

“That is really impactful for patients and really highlights why we do what we do, which is to try to address areas of high unmet need and patients who have very difficult-to-treat tumors,” Krivoshik said.

Krivoshik also provided an overview of the company’s oncology pipeline.

“Not only do we continue to move our agents that are already approved for more advanced disease states earlier in the disease continuum, we have a number of other late-stage agents that continue to progress,” Krivoshik said. – by Mark Leiser

Reference: Petrylak DP, et al. Abstract. LBA4505. Presented at: ASCO Annual Meeting; May 31-June 4, 2019; Chicago.